US-China Trade Tensions Poses Risk To Merit Medical's $150 Million Revenue From China

Merit Medical Systems Inc. (NASDAQ:MMSI) is scheduled to release its first quarter 2025 adjusted EPS of 75 cents and sales of $352.82 million, as per data on Benzinga Pro.

Merit develops, manufactures and distributes proprietary medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy.

Barrington Research writes that in 2024, about 41% of Merit Medical’s revenue of $1.36 billion was generated outside of the U.S., and about 11% of Merit Medical’s 2024 revenue was generated in China.

Also Read: Stellantis Q1 Shipments Decline 9%, but Gains in South America and EU Offer Relief

Analyst Michael Petusky also highlights the company’s several manufacturing and packaging facilities outside of the U.S., including in Mexico, Brazil, ...

https://www.benzinga.com/general/health-care/25/04/44771937/us-china-trade-tensions-poses-risk-to-merit-medicals-150-million-revenue-from-china